BioIVT Appoints Dr. Auro Nair as Chief Executive Officer
Woodbury, New York (February 2, 2026) – BioIVT, a leading provider of mission-critical biological specimens for the pharmaceutical research and development and diagnostic markets, today announced that Dr. Auro Nair has been appointed as its Chief Executive Officer. Dr. Nair has served on the company’s Board of Directors since June 2024.
“We are thrilled to welcome Dr. Nair as BioIVT’s CEO,” said Piyush Shukla, Chairman of the Board and Partner at Linden Capital Partners. “Auro brings deep commercial and operational skills and a career-long commitment to advancing life science research and development. His leadership will help strengthen our strong foundation and advance our mission to serve the global research community. I also want to thank outgoing CEO Dr. Richard Haigh for his stewardship of the company over the last three and a half years and wish him well in his future endeavors.”
Dr. Nair brings more than 30 years of experience in pharma services and life sciences. Most recently, he served as Executive Vice President of The Jackson Laboratory and President of its Mice, Clinical & Research Services business, where he led 16 years of sustained double-digit growth, supporting drug discovery and the development of precision medicine platforms. Earlier in his career, he held leadership roles at Caliper Life Sciences and GlaxoSmithKline. He earned a bachelor’s degree in chemistry from Universiti Sains Malaysia, an MBA from Suffolk University, and a PhD in chemistry from the University of Oklahoma.
“I am honored to join BioIVT and lead an organization whose work is highly critical to the development of new therapeutics,” said Dr. Nair. “BioIVT’s high-quality biospecimens, cell-based models, and large data-cohorts, enable researchers to make better choices to accelerate drug development and pursue therapies that can meaningfully improve patient outcomes. The dedication of our employees, from donor center teams to laboratory specialists to global sales and operations, is what makes this mission possible. I am excited to support them as we continue to grow and deliver even greater value to our customers and partners worldwide.”
About BioIVT
BioIVT is a leading provider of mission-critical biological specimens for the pharmaceutical and diagnostic markets. The company specializes in control and disease-state samples, including tissues, immune cell products, blood, and other biofluids. BioIVT’s portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. For more information, please visit www.bioivt.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is the largest dedicated healthcare private equity firm. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Since its founding, Linden has invested in over 45 healthcare companies encompassing over 350+ total transactions across its strategies. The firm currently manages over $13.0 billion of regulatory assets under management. For more information, please visit www.linden.com.